Predictors of LDL-C target non-attainment in patients with type 2 diabetes with obesity and very high cardiovascular risk
Main Article Content
Abstract
Type 2 diabetes mellitus (T2DM) is a metabolic disorder that increases the risk of atherosclerotic cardiovascular disease, particularly in obese patients. Controlling low-density lipoprotein cholesterol (LDL-C) is the key therapeutic target in reducing cardiovascular risk. However, domestic data on factors influencing LDL-C goal attainment in this population remain limited. A cross-sectional study was conducted on 138 obese T2DM patients treated with statins for at least 3 months at Nguyen Tri Phuong Hospital from April 2024 to October 2024. Results showed that 120 patients (86.9%) did not achieve the LDL-C goal, of whom 89.7% had central obesity. Central obesity was identified as a predictor of LDL-C goal non-attainment (odds ratio [OR] = 3.782; 95% confidence interval [CI]: 1.123 – 12.740), whereas high treatment adherence assessed by the Morisky-8 scale was significantly reducing this risk (OR = 0.196; 95% CI: 0.041 – 0.944). These findings highlight the importance of managing central obesity and strengthening treatment adherence strategies to improve LDL-C control in obese T2DM patients.
Article Details
Keywords
LDL-C, type 2 diabetes mellitus, obesity, waist-to-hip ratio, dyslipidemia
References
2. Klop B, Elte JWF, Castro Cabezas M. Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients. 2013; 5(4): 1218-1240. doi:10.3390/nu5041218.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the european society of cardiology (ESC) and european atherosclerosis society (EAS). European Heart Journal. 2019; 41(1): 111-188. doi:10.1093/eurheartj/ehz455.
4. Zhou X, Ji L, Ran X, et al. Prevalence of Obesity and Its Influence on Achievement of Cardiometabolic Therapeutic Goals in Chinese Type 2 Diabetes Patients: An Analysis of the Nationwide, Cross-Sectional 3B Study. PLoS One. 2016; 11(1): e0144179. doi:10.1371/journal.pone.0144179.
5. Nguyen HT, Ha KPT, Nguyen AH, Nguyen TT, Lam HM. Non-achievement of the Low-Density Lipoprotein Cholesterol Goal in Older Patients with Type 2 Diabetes Mellitus and a Very High Cardiovascular Disease Risk: A Multicenter Study in Vietnam. Ann Geriatr Med Res. 2021; 25(4): 278-285. doi:10.4235/agmr.21.0099.
6. Committee ADAPP. 2. Diagnosis and classification of diabetes: Standards of care in diabetes-2024. Diabetes Care. 2023; 47(Supplement_1): S20-S42. doi:10.2337/dc24-S002.
7. Organization WH, others. The Asia-Pacific perspective: redefining obesity and its treatment. http://www who int/bmi/index jsp? introPage= intro_3 html. 2000.
8. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the european society of cardiology (ESC) and the european society of hypertension (ESH). European Heart Journal. 2018; 39(33): 3021-3104. doi:10.1093/eurheartj/ehy339.
9. Trường PH, Khoa ĐĐ, Khánh VHX, Anh NH, Hải NH. Cập nhật chẩn đoán và điều trị suy tim phân suất tống máu bảo tồn: 1. 2024; 3(1): 12-12.
10. Ibrahim A. IDF Clinical Practice Recommendation on the Diabetic Foot: A guide for healthcare professionals. Diabetes Res Clin Pract. 2017; 127: 285-287. doi:10.1016/j.diabres.2017.04.013.
11. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6): 2089-2100. doi:10.1111/j.1523-1755.2005.00365.x.
12. Eknoyan G, Lameire N, Eckardt KU, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements. 2013; 3(1): 5-14. doi:10.1038/kisup.2012.73.
13. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403): 157-163. doi:10.1016/S0140-6736(03)15268-3.
14. Grover A, Oberoi M, Rehan HS, Gupta LK, Yadav M. Self-reported Morisky Eight-item Medication Adherence Scale for Statins Concords with the Pill Count Method and Correlates with Serum Lipid Profile Parameters and Serum HMGCoA Reductase Levels. Cureus. 12(1): e6542. doi:10.7759/cureus.6542.
15. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. August 2025: ehaf190. doi:10.1093/eurheartj/ehaf190.
16. The Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011; 377(9784): 1085-1095. doi:10.1016/S0140-6736(11)60105-0.
17. Tsai HS, Tseng WK, Yin WH, et al. The Correlation between Waist-Hip Ratio and Achieving Therapeutic Lipid Goals in Taiwan. Acta Cardiol Sin. 2019; 35(6): 605-614. doi:10.6515/ACS.201911_35(6).20190403A.
18. S CM, Vijaykumar S, G PA. Type 2 diabetes mellitus with dyslipidemia: risk factors, prevalence, pathophysiology, and nutritional management-a narrative review. International Journal Of Community Medicine And Public Health. 2025; 12(6): 2900-2908. doi:10.18203/2394-6040.ijcmph20251741.